MedTrace Logo

Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis

NCT02953106 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-04-08

No results posted yet for this study

Summary

Single centre, double-blind, placebo controlled, adaptive design, cross-over trial. The primary objective is to assess the additive effects of using combined intranasal fluticasone propionate plus azelastine nasal spray on airway hyperresponsiveness. This is in patients with persistent asthma and allergic rhinitis, receiving inhaled steroid.

Conditions

  • Asthma, Allergic
  • Rhinitis,Allergic
  • Allergy

Interventions

DRUG

Azelastine-Fluticasone Nasal

137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate

DRUG

Placebos

Placebo nasal spray

Sponsors & Collaborators

  • University of Dundee

    lead OTHER

Principal Investigators

  • Brian Lipworth, MD · Scottish Centre for Respiratory Reseach

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-20
Primary Completion
2018-09-10
Completion
2018-09-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02953106 on ClinicalTrials.gov